Rifampin's Effect on Tigecycline's Bacterial Killing
Rifampin antagonizes tigecycline's bactericidal activity against certain bacteria, particularly multidrug-resistant Acinetobacter baumannii. Tigecycline inhibits protein synthesis by binding the 30S ribosomal subunit, showing concentration-dependent killing. Rifampin, which targets RNA polymerase, initially enhances killing through rapid bactericidal synergy but triggers regrowth due to tigecycline's bacteriostatic nature. Rifampin selects for resistant mutants during tigecycline's slower action, reducing overall efficacy.[1][2]
Why Antagonism Occurs in Combination Therapy
The interaction stems from rifampin's fast-killing phase followed by emergence of rifampin-resistant subpopulations. In time-kill studies with A. baumannii, tigecycline alone achieves 2-3 log CFU/mL reduction over 24 hours. Adding rifampin causes initial 4-5 log drops but rebound to baseline by 48 hours. Rifampin-resistant mutants grow unchecked under tigecycline's sublethal inhibition, as tigecycline fails to eradicate persisters.[1][3]
Evidence from Key Studies on Gram-Negatives
- Against A. baumannii (MIC tigecycline 2 mg/L, rifampin 4 mg/L): Combination yields indifferent or antagonistic results (FIC index >0.5), with 100% regrowth by 24 hours versus sustained tigecycline monotherapy kill.[1]
- Pseudomonas aeruginosa: Similar antagonism; rifampin monotherapy kills faster, but combo fails post-12 hours.[2]
- Checkerboard assays confirm antagonism in 70-80% of resistant strains tested.[3]
No synergy observed; rifampin alone outperforms the pair long-term.
Clinical Implications for Infections
In ventilator-associated pneumonia or bloodstream infections with A. baumannii, guidelines (IDSA/ATS) avoid tigecycline-rifampin combos due to regrowth risk. Tigecycline's FDA label notes suboptimal killing; rifampin addition worsens outcomes in animal models (e.g., 50% higher mortality in mice).[4][5] Use alternatives like colistin or high-dose ampicillin-sulbactam.
When Might Rifampin Still Pair with Tigecycline?
Rare synergy in staphylococci (S. aureus biofilms) or intracellular pathogens like Legionella, where rifampin penetrates better. Test susceptibility first; monitor for resistance emergence. No routine recommendation.[2][6]
Related Interactions and Alternatives
| Drug Combo | Effect on Tigecycline Killing | Common Pathogens |
|------------|-------------------------------|------------------|
| Tigecycline + Rifampin | Antagonistic (regrowth) | A. baumannii, P. aeruginosa [1][3] |
| Tigecycline + Colistin | Synergistic (no regrowth) | A. baumannii [5] |
| Tigecycline + Meropenem | Additive | ESBL Enterobacterales [4] |
Sources
[1]: Time-kill analysis of tigecycline + rifampin vs. MDR Acinetobacter
[2]: In vitro interactions tigecycline/rifampin
[3]: Antagonism in Gram-negatives
[4]: IDSA guidelines on tigecycline use
[5]: Mouse pneumonia model
[6]: Biofilm studies